卵巢上皮癌肿瘤细胞减灭术后奈达铂联合紫杉醇治疗分析

目的：分析卵巢上皮癌患者在肿瘤减灭术后采用奈达铂联合紫杉醇治疗的临床效果。方法：将到本院行肿瘤细胞减灭术治疗的68例卵巢上皮癌患者按随机数字平均分为两组，A组采用顺铂联合紫杉醇化疗，B组采用奈达铂联合紫杉醇化疗，观察比较两组化疗效果。结果：A、B组化疗1个周期后总缓解率分别为64．71％、70．59％，两组总缓解率比较差异不显著（P〉0．05）；A、B组化疗3个周期后总缓解率分别为70．59％、91．18％，B组总缓解率高于A组（P〈0．05）；A、B组3年生存率分别为67．64％、79．41％，两组2年生存率比较差异不显著（P〉0．05）；A、B组平均生存期分别为（39．5±3．2）个月、（40．1±2．9）个月，两组平均生存期比较差异不显著（P〉0．05）；B组严重毒副反应发生率少于A组（P〈0．05）。结论：对于卵巢上皮癌患者在疗效理想的肿瘤细胞减灭术后给予奈达铂联合紫杉醇化疗，能显著提高患者的生存时间，减少4g,,J反应。

Analysis of Nedaplatin Joint paclitaxel in the Treatment of Pithelial Ovarian Cancer after Cytoreductive Surgery

Objective： To analyze the clinical effect of nedaplatin joint paclitaxel in the treatment of pithelial ovarian cancer after cytoreductive surgery. Method： 68 cases of epithelial ovarian cancert which underwent cytoreductive surgery were average randomly divided into two groups, group A were treated by cis- platin joint paclitaxel, while group B were treated by nedaplatin joint pacl＇itaxcl, observed the treatment effect of two group. Result： Overall response rate of 1st cycle of group A, B was 64.71% ,70.59%, difference of overall response rate between two groups was not significant （ P〉 0.05 ） ; overall response rate of 6th cycle of group A,B was 70.59 % ,91.18%, overall response rate of B group was higher than group A （P 〈0.05） ; 3-year survival rate of group A,B was 67.64 % ,79.41%, difference of 3-year survival rate between two groups was not significant （P〉 0.05 ） ;average survival period of group A, B was （39.5 ±3.2 ） months , （ 40. 1 ± 2.9） months, difference of mean survival time of two groups was not significant （ P〉 0.05 ） ; the in- cidence of serious toxicity of group B was less than group A （ P 〈0.05 ）. Conclusion： Patients with epithelial ovarian cancer, treated by nedaplatin joint paclitaxel after eytoreductive surgery can significantly increase sur- vival time of patients and reduce toxicity.